A Multinational, Observational Study to Investigate the Efficacy, Safety and Tolerability of Acarbose as Add-On or Monotherapy in a Range of Patients: The GlucoVIP Study

@article{Zhang2013AMO,
  title={A Multinational, Observational Study to Investigate the Efficacy, Safety and Tolerability of Acarbose as Add-On or Monotherapy in a Range of Patients: The GlucoVIP Study},
  author={Weiwei Zhang and DongJun Kim and Elizabeth Philip and Zahid Miyan and Irina Nikolaevna Barykina and Birgit Schmidt and Herbert Stein},
  journal={Clinical Drug Investigation},
  year={2013},
  volume={33},
  pages={263-274}
}
Background and ObjectivesThe burden of type 2 diabetes mellitus is growing rapidly, particularly in the Asia-Pacific region. The aim of this international, large-scale, observational study was to investigate the efficacy and tolerability of the antidiabetic agent acarbose as add-on or monotherapy in a range of patients with type 2 diabetes, including those with cardiovascular morbidities. The majority of practices were included from high-burden regions (predominantly those in the Asia-Pacific… Expand
Acarbose improves glycemic control as add-on or monotherapy in Indian type-2 diabetes: Findings from the GlucoVIP multinational observational study
TLDR
Acarbose is effective and safe in Indian patients with type-2 diabetes mellitus (T2DM), it helps in weight reduction and has very good compliance in patients with T2DM. Expand
Alpha-glucosidase inhibitor, acarbose, improves glycamic control and reduces body weight in type 2 diabetes: Findings on indian patients from the pooled data analysis
TLDR
The results of this observational study suggest that acarbose was effective and well tolerated in the Indian patients with T2DM. Expand
Acarbose improves glycemic control and reduces body weight: Subanalysis data of South Asia region
TLDR
Post-hoc analysis of real-life data showed acarbose treatment improved glycaemic control and reduced the BW in Asian patients from South Asia region, consistent with RCT meta-analyses. Expand
Alpha-glucosidase inhibitors and hepatotoxicity in type 2 diabetes: a systematic review and meta-analysis
TLDR
Meta-analysis showed that AGIs might increase the risk of hepatotoxicity, and higher dose appeared to be associated with higher risk of hepatitis, however, the evidence is limited with surrogate measures (i.e. ALT and AST), and no clinically important adverse events were observed. Expand
Combination Therapy When Metformin Is Not an Option for Type 2 Diabetes
TLDR
Treatment approaches should be individualized for vulnerable patient populations for whom metformin is not appropriate, and selecting the most appropriate combination therapy for patients with T2DM requires balancing clinical benefits with the risks, such as weight gain and hypoglycemia. Expand
Use of an α-Glucosidase Inhibitor and the Risk of Colorectal Cancer in Patients With Diabetes: A Nationwide, Population-Based Cohort Study
TLDR
A nationwide, population-based study using a large cohort with diabetes in the Taiwan National Health Insurance Research Database found that acarbose use reduced the risk of incident colorectal cancer in patients with Diabetes in a dose-dependent manner. Expand
Investigation of bioequivalence of a new fixed‐dose combination of acarbose and metformin with the corresponding loose combination as well as the drug–drug interaction potential between both drugs in healthy adult male subjects
TLDR
The bioequivalence of the acarbose/metformin FDC compared with the individual agents administered simultaneously (loose combination) was investigated and the safety and tolerability of the FDC and the potential for drug–drug interactions were investigated. Expand
Network Meta-Analysis of the Therapeutic Effects of Hypoglycemic Drugs and Intensive Lifestyle Modification on Impaired Glucose Tolerance.
TLDR
A network meta-analysis in patients with IGT found that acarbose and metformin were associated with decreased rates of progression to diabetes and increased rates of achieving a normal glucose level, while intensive lifestyle modification was not. Expand
Safety of a Novel Weight Loss Combination Product Containing Orlistat and Acarbose
TLDR
The delay in the rise of orlistat plasma concentration indicates that the modified-release properties of the MR-OA formulation are effective, and it can be assumed that the safety profile regarding the or listat moiety of MR-oa is comparable to the conventional orlistats and a promising approach for weight control in obese patients. Expand
Dose Modification of Antidiabetic Agents in Patients with Type 2 Diabetes Mellitus and Heart Failure
TLDR
A group of experts from across India were involved in a consensus meeting in Pondicherry during the National Insulin Summit in November 2015, to assist the clinicians while treating patients with T2DM and heart failure. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 50 REFERENCES
Safety and efficacy of acarbose in the treatment of Type 2 diabetes: data from a 5-year surveillance study.
  • G. Mertes
  • Medicine
  • Diabetes research and clinical practice
  • 2001
TLDR
The results suggest that when used in long-term day-to-day management of diabetes, acarbose is well tolerated and can improve glycaemic control as monotherapy, as well as in combination therapy. Expand
Evaluation of the Efficacy and Tolerability of Acarbose in Patients with Diabetes Mellitus
TLDR
The therapeutic benefit and good tolerability and compliance of acarbose as mono- and combination therapy, even in elderly and multimorbid patients are documents. Expand
The use of acarbose in the primary-care setting: evaluation of efficacy and tolerability of acarbose by postmarketing surveillance study.
TLDR
The therapeutic benefit and the good tolerability of acarbose were examined in a postmarketing surveillance study and laboratory investigations gave no indication of other adverse effects, e.g. elevated levels of transaminases or creatinine. Expand
International noninterventional study of acarbose treatment in patients with type 2 diabetes mellitus.
TLDR
Acarbose therapy was efficacious and well tolerated in daily life in patients with type 2 diabetes and was maintained over the 2-year extension period. Expand
Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial
TLDR
Evaluating the metabolic effects of acarbose and repaglinide in type 2 diabetic patients who are being treated with a sulphonylurea–metformin combination therapy found the same treatment was associated with a significant increase in body weight and the increase was reversed during the cross-over phase. Expand
Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study.
TLDR
Acarbose and metformin are effective drugs for the first line monotherapy of patients with NIDDM and both active drugs showed the same improvement of efficacy criteria compared with placebo. Expand
Efficacy and safety profile evaluation of acarbose alone and in association with other antidiabetic drugs: a systematic review.
TLDR
When current therapy is not adequate to obtain glycemic control, acarbose could be an option as monotherapy and as an add-on to other antidiabetic drug treatment, especially when postprandial hyperglycemia is the main concern. Expand
Efficacy of 24-Week Monotnerapy With Acarbose, Glibenclamide, or Placebo in NIDDM Patients: The Essen Study
TLDR
Acarbose and glibenclamide are effective drugs for the monotherapy of NIDDM patients when diet alone fails and postprandial insulin increase has been shown to be associated with increased risk for cardiovascular disease. Expand
Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.
TLDR
This study suggests that treating IGT patients with acarbose is associated with a significant reduction in the risk of cardiovascular disease and hypertension. Expand
Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes
TLDR
Acarbose is a valuable option for the management of type 2 diabetes and, as the only oral antidiabetes agent approved for the treatment of prediabetes, can help to improve clinical management across the dysglycaemic disease continuum. Expand
...
1
2
3
4
5
...